BioClinica Expands Operational Capabilities, Opens New European Offices
NEWTOWN, PA, June 30, 2015– BioClinica®, Inc., the world’s leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe. The state-of-the-art facilities will offer an array of clinical trial services including medical imaging, site training and support, and eClinical product lines to meet the growing need of European drug and medical device sponsors. BioClinica‘s clients include top pharmaceutical, biotechnology, and medical device companies as well as CRO partnerships in Europe and across the globe.
“Our new offices will serve as important hubs that enable efficient delivery of tailored resources to our European and Global clients” said John Hubbard, BioClinica’s CEO. “Infrastructure investments and the recruitment of local scientific, medical, and regulatory expertise highlights BioClinica’s firm commitment to supporting clinical drug development in Europe”.
Together, the London and Munich offices offer a combined space of 1,400 square metersto support clinical trial services across key therapeutic areas. With a focus on medical imaging, the European offices will showcase an advanced image analysis center for BioClinica’s extensive network of European radiologists and imaging specialists. “Our expansion will provide the resources needed for regional scientific and medical experts to assemble and deliver high quality central review of imaging data for multisite trials in Europe” said David Herron, BioClinica’s President of Medical Imaging, Cardiovascular Safety, and Molecular Markers.
BioClinica is holding an open house event for the London office on July 2nd for clients, sponsors, and partners in which members of the Executive Leadership team and representatives from BioClinica’s Medical Imaging and Biomarker, Site network and patient recruitment, and eClinical business segments will be on hand to discuss and demonstrate clinical trial capabilities.
BioClinica is poised to expand its eClinical division in Europe, delivering products and showcasing technologies that facilitate efficient drug development in the region. “Our newly expanded offices provide an interactive environment for training and demonstration of our eClinical technology suite” said Mukhtar Ahmed, President of eClinical Solutions.
The London office is located at 72 Hammersmith Road and the Munich office is located at Landsberger Strasse 290. BioClinica has plans for an Open House at the Munich office later this summer.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
